Stocks · News reference

VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients

Aug 26, 2026, 12:21 PMBenzinga Newsdesk

Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the findings

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VNRX

Source: benzinga
Observed: Aug 26, 2026, 12:21 PM
Checked: Aug 26, 2026, 12:21 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 27, 2026, 2:02 PMAvi Kapoor
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change Agents down 29%, and Xiao-I down 21%.
Read original at benzinga
AIXI AMOD CHGA MIMI NVDA
BenzingaAug 27, 2026, 11:35 AMVandana Singh
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
Read original at benzinga
VNRX
BenzingaAug 27, 2026, 9:56 AMAvi Kapoor
Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech stocks saw gains in early trading.Salesforce (NYSE: CRM) jumps on strong Q2 results and raised guidance, tech stocks up in pre-market trading.
Read original at benzinga
AIXI AXG AXTI CRE CRM
BenzingaAug 26, 2026, 4:23 PMBenzinga Newsdesk
VolitionRx shares are trading lower. The company announced the publication of a peer‑reviewed paper and editorial showing its Nu.Q NETs H3.1 biomarker predicts 28‑day mortality and need for renal replacement therapy in sepsis patients.
Read original at benzinga
VNRX

VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients

Connected markets

Related headlines

Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

VolitionRx shares are trading lower. The company announced the publication of a peer‑reviewed paper and editorial showing its Nu.Q NETs H3.1 biomarker predicts 28‑day mortality and need for renal replacement therapy in sepsis patients.